Similar companies
Income Statement (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Revenue | 52M | 24.8% |
| Gross Profit | 17M | 31.8% |
| Cost of Revenue | 35M | 21.7% |
| Operating expense | 73M | 6.5% |
| Net Income | -7.2M | 86.2% |
| EBITDA | 3.1M | 105.7% |
Balance Sheet (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Total Assets | 955M | 10.2% |
| Total Liabilities | 114M | 24.6% |
| Total Equity | 841M | 8.5% |
| Shares Outstanding | 19M | 3.6% |
Cash Flow (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Cash from operations | 37M | 174.4% |
| Cash from investing | -47M | 15.1% |
| Cash from financing | 55M | 480.3% |
EPS
Financial Highlights for Ligand Pharmaceuticals in Q3 '24
Ligand Pharmaceuticals reported a revenue of 52M, which is a 24.8% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 17M, marking a 31.8% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 35M, a 21.7% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 73M, showing a -6.5% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -7.2M, showing a 86.2% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was 3.1M, showing a 105.7% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for Ligand Pharmaceuticals with growth in revenue, gross profit, and net income.
